L-methionine suppresses pathological sequelae of cis-platinum in the rat.
The pathological changes characteristically observed in the kidney, bone marrow, thymus, spleen, and duodenum of the rat given 12.2 mg/kg of cis-platinum (CDDP) ip are reduced or eliminated when a CDDP solution containing a 20-fold excess of L-methionine to cis-platinum is administered. L-Methionine was also effective in reducing the renal toxicity induced by CDDP when given orally 20 min before the iv administration of 7.5 mg CDDP/kg. L-Methionine did not compromise the efficacy of CDDP when the antitumor activity of the combination of L-methionine and CDDP was measured against the Walker 256 carcinosarcoma in the rat. No significant reduction in the antitumor activity of the CDDP resulted from the parenteral administration of L-Methionine when evaluated against the L1210 murine leukemia. The oral administration of L-methionine (500 mg/kg) 30 min after the administration of CDDP has no significant effect on the antitumor activity of CDDP in mice bearing the L1210 murine leukemia. The results suggest that L-methionine may have some practical utility in the control of certain aspects of CDDP toxicity.
Basinger
M A
MA
Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37235.
Jones
M M
MM
Holscher
M A
MA
D000818:Animals; D001806:Blood Urea Nitrogen; D001853:Bone Marrow / Q000473:pathology; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D002945:Cisplatin / Q000037:antagonists & inhibitors / Q000627:therapeutic use / Q000633:toxicity*; D003404:Creatinine / Q000097:blood; D005260:Female; D007668:Kidney / Q000473:pathology; D007939:Leukemia L1210 / Q000188:drug therapy; D008715:Methionine / Q000494:pharmacology*; D010984:Platinum / Q000493:pharmacokinetics; D051381:Rats; D011919:Rats, Inbred Strains; D013154:Spleen / Q000473:pathology; D013950:Thymus Gland / Q000473:pathology
D010984:Platinum; D008715:Methionine; D003404:Creatinine; D002945:Cisplatin